Is Dhanvantri Jeev. overvalued or undervalued?

As of 26 September 2025, Dhanvantri Jeev. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its current metrics. Key ratios include a PE Ratio of 12.20, an EV to EBITDA of 9.65, and a PEG Ratio of 0.26, which suggests that the stock is trading at a lower valuation compared to its growth prospects.
When compared to peers, Dhanvantri Jeev. shows a more favorable valuation with Apollo Hospitals at a PE of 68.57 and Max Healthcare at a staggering 91.13. This indicates that Dhanvantri Jeev. is significantly undervalued relative to these competitors. Furthermore, the company's stock has outperformed the Sensex in various time frames, including a 52.62% return over the past year compared to a -6.30% return for the index, reinforcing the notion that it may be undervalued in the current market environment.